A P2Y12 inhibitor, such as clopidogrel or ticagrelor, might be a better choice than aspirin for antiplatelet monotherapy in patients with coronary artery disease, results of a new meta-analysis ...

A commonly prescribed drug could be more effective than aspirin for long-term heart disease prevention. Analysis of nearly 29,000 patients with coronary artery disease (CAD) suggests the blood thinner ...

More-aggressive antiplatelet therapy with a P2Y12 inhibitor—either clopidogrel or ticagrelor (Brilinta; AstraZeneca)—for secondary prevention is associated with a lower risk of atherothrombotic events ...

Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke as compared with aspirin alone when treatment is initiated early (≤24 hours) after an acute mild stroke. The effect of ...

Patients who received a single antiplatelet drug therapy— usually aspirin — after transcatheter aortic valve replacement (TAVR) had about half the risk of dying in the subsequent 6 months compared ...

CHICAGO -- For prolonged antithrombotic treatment after percutaneous coronary intervention (PCI), clopidogrel monotherapy was more effective and at least as safe as aspirin monotherapy in a high-risk ...